Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies

Table 1 Demographics of cases used for proteomics and candidate validation in medial frontal cortex tissue

Case	Clin.Dx	Path.Dx	Sex	ER	AAO	AAD	DD	BS	TP	CERAD	ABC	NIH.R	APOE	EXP	%TB
1	AD	AD	M	W	67	73	6	VI	5	Frequent	A3B3C3	High	33	P	8.9
2	AD	AD	F	W	64	87	23	V	3	Moderate	A2B3C2	High	NA	P	4.7
3	AD v. VaD	AD	M	W	66	73	7	V	5	Moderate	A3B3C2	High	NA	P	5.1
4	EOAD	AD	F	W	48	58	10	VI	5	Frequent	A3B3C3	High	NA	P	18.7
5	AD	AD	F	W	81	83	2	VI	5	Moderate	A2B3C2	High	NA	P	1.1
6	AD	AD	M	W	69	77	8	VI	5	Moderate	A2B3C2	High	44	P + V	4.6
7	AD v. FTD	AD	M	W	62	73	11	V	4	Moderate	A3B3C2	High	NA	V	NA
8	AD	AD	F	W	60	86	26	V	5	Moderate	A3B3C2	High	NA	V	NA
9	FTD (SD)	PiD	M	W	62	74	12	0	0	None	A0B0C0	Not	33	P	2.9
10	FTD	PiD	F	H	59	68	9	II	2	None	A1B1C0	Low	33	P	2.1
11	FTD	PiD	F	W	61	68	7	I	0	None	A0B1C0	Not	33	P	3.4
12	FTDP	PiD	M	H	65	81	16	I	0	None	A0B1C0	Not	33	P + V	5.3
13	FTD/PPA	PiD	F	W	47	61	14	0	0	None	A0B0C0	Not	NA	V	NA
14	FTD	PiD	M	W	67	75	8	IV	3	None	A2B2C0	Intermediate	NA	V	NA
15	PNFA	CBD	M	W	68	70	2	II	1	None	A1B1C0	Low	34	P	8.3
16	FAD v. FTD	CBD	M	W	60	70	10	0	0	None	A0B0C0	Not	33	P	4.8
17	PSP v. FTD	CBD	F	H	48	55	7	0	0	None	A0B0C0	Not	34	P	5.5
18	AD	CBD	F	W	70	78	8	III	0	None	A0B2C0	Not	33	P	9.7
19	CBD	CBD	F	W	61	68	7	II	2	None	A1B1C0	Low	34	P	4.5
20	AD v. VaD	CBD	F	W	86	89	3	III	2	None	A1B2C0	Not	NA	P + V	3.8
21	PPA	CBD	M	W	50	55	5	0	0	None	A0B0C0	Not	33	V	NA
22	CBD	CBD	F	W	64	67	3	I	0	None	A0B1C0	Not	NA	V	NA
23	PSP	PSP	M	W	59	66	7	I	1	None	A1B1C0	Low	34	P	0.4
24	PPA v. PSP	PSP	F	W	66	71	5	0	2	None	A1B0C0	Low	33	P + V	0.3
25	PSP/AGD	PSP	F	W	55	61	6	III	0	None	A0B2C0	Not	NA	V	NA
26	PSP	PSP	F	H	55	62	7	0	0	None	A0B0C0	Not	NA	V	0.1
27	NA	PART	M	H	NA	78	NA	II	0	None	A0B1C0	Low	33	P	0.0
28	NA	PART	F	W	NA	92	NA	III	1	None	A1B2C0	Not	33	P	0.0
29	NA	PART	M	H	NA	88	NA	III	0	None	A0B2C0	Not	33	P	0.0
30	NA	PART	M	W	NA	89	NA	III	0	None	A0B2C0	Not	23	P	0.0
31	NA	PART	M	W	NA	74	NA	III	0	None	A0B2C0	Not	NA	P	0.0
32	NA	PART	F	W	NA	94	NA	I	2	None	A1B1C0	Low	33	P + V	0.0
33	NA	CTL	M	W	NA	68	NA	I	0	None	A0B1C0	Low	NA	V	NA
34	NA	CTL	F	W	NA	97	NA	II	2	None	A1B1C0	Low	NA	V	NA
35	NA	CTL	F	W	NA	24	NA	0	0	None	A3B3C3	Not	NA	V	NA

Abbreviations: AAO age at onset, AAD age at death, ABC Amyloid Thal phase, tau Braak Stage, neuritic plaque score (CERAD), AGD argyrophilic grain disease, AD Alzheimer’s disease, APOE apolipoprotein E alleles, BS Braak stage, CERAD consortium to establish a registry of Alzheimer’s disease- neuritic plaque score, CBD corticobasal degeneration, Clin. Dx clinical diagnosis, CTL unaffected control case, DD disease duration, ER ethno-racial status, EOAD early onset Alzheimer’s disease, EXP experimental use of case, FAD familial Alzheimer’s disease, FTD frontotemporal dementia, NIH.R National Institute of Health Reagan Score, P ProPPr proteomics use, Path. Dx primary pathological diagnosis, PART primary age related tauopathy, PiD Pick’s disease, PPA primary progressive aphasia, sAD sporadic AD, SD semantic dementia, TP Thal Phase, V Validation of candidate protein case use, VaD vascular dementia, M male, F female, NA not applicable, %TB AT8 phospho-tau burden percent coverage in medial frontal cortex tissue used for ProPPr experiments

ISSN: 1750-1326